구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | peptide specific dendritic cell (peptide specific dendritic cell) Beijing Doing Biomedical Co., Ltd.·Leukemia, Acute Lymphocytic (ALL) 30 trials |
|---|---|
Overview Program | peptide specific dendritic cell |
Overview Company | Beijing Doing Biomedical Co., Ltd. |
Overview Modality | CGT |
Overview Target | Leukemia, Acute Lymphocytic (ALL) |
Overview Indication | Leukemia, Acute Lymphocytic (ALL); Leukemia, Acute Myelogenous (AML) |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Targeting oral squamous cell carcinoma with venom peptides: mechanisms, selectivity and translational potential.. Venom-derived peptides represent a promising new class of biotherapeutics for oral squamous cell carcinoma (OSCC), offering intrinsic tumor selectivity and multimodal anticancer activity that address key limitations of current chemoradiotherapy. By exploiting the aberrant biophysical f… |
Clinical Safety signal | Targeting oral squamous cell carcinoma with venom peptides: mechanisms, selectivity and translational potential.. Venom-derived peptides represent a promising new class of biotherapeutics for oral squamous cell carcinoma (OSCC), offering intrinsic tumor selectivity and multimodal anticancer activity that address key limitations of current chemoradiotherapy. By exploiting the aberrant biophysical f… |
Clinical Program phase | PHASE_1 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | peptide specific dendritic cell (peptide specific dendritic cell) Beijing Doing Biomedical Co., Ltd.·Leukemia, Acute Lymphocytic (ALL) 30 trials |
|---|---|
Overview Program | peptide specific dendritic cell |
Overview Company | Beijing Doing Biomedical Co., Ltd. |
Overview Modality | CGT |
Overview Target | Leukemia, Acute Lymphocytic (ALL) |
Overview Indication | Leukemia, Acute Lymphocytic (ALL); Leukemia, Acute Myelogenous (AML) |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Targeting oral squamous cell carcinoma with venom peptides: mechanisms, selectivity and translational potential.. Venom-derived peptides represent a promising new class of biotherapeutics for oral squamous cell carcinoma (OSCC), offering intrinsic tumor selectivity and multimodal anticancer activity that address key limitations of current chemoradiotherapy. By exploiting the aberrant biophysical f… |
Clinical Safety signal | Targeting oral squamous cell carcinoma with venom peptides: mechanisms, selectivity and translational potential.. Venom-derived peptides represent a promising new class of biotherapeutics for oral squamous cell carcinoma (OSCC), offering intrinsic tumor selectivity and multimodal anticancer activity that address key limitations of current chemoradiotherapy. By exploiting the aberrant biophysical f… |
Clinical Program phase | PHASE_1 |
추천 비교
추천 비교